• Kite Pharma flagged new clinical updates across its oncology pipeline, with results already presented at ASCO and EHA 2026 and additional data slated for those meetings in late May and mid-June.
• The most commercially relevant readouts center on investigational anitocabtagene autoleucel in relapsed or refractory multiple myeloma, with manufacturing experience data positioned to support broader development ahead of potential launch planning.
• At EHA, updated Phase 1 findings for KITE-753 in relapsed or refractory B-cell lymphoma showed encouraging safety and durability, supporting continued development.
• The disclosures also highlighted progress in earlier-stage cell therapy work in solid tumors, including an updated Phase 1 CAR T dataset in recurrent glioblastoma presented by an academic collaborator.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kite Pharma Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.